Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas - 26/08/11
, Stéphane Richard, MD, PhD cAbstract |
Purpose |
To test the efficacy of the novel vascular endothelial growth factor (VEGF) receptor inhibitor SU5416, in a case of refractory von Hippel-Lindau (VHL) retinal hemangioblastoma (RHB).
Design |
Interventional case report.
Methods |
Patient included in a multicenter phase II trial. A 30-year-old woman presenting with VHL disease and multiple RHB on her only eye, refractory to conventional treatments, had decreased visual acuity due to cystoid macular edema (CME). SU5416 was administered intravenously for 7 months. Best-corrected visual acuity (BCVA) and macular thickness were measured by optical coherence tomography.
Results |
Under treatment, the size of the RHB did not change, but CME improved significantly. Best-corrected visual acuity rose from 20/40 to 20/25. However, CME recurred after the end of the treatment.
Conclusion |
The VEGF receptor inhibitor SU5416 failed to reduce the size of RHB but was very effective for the associated CME.
Le texte complet de cet article est disponible en PDF.| ☆ | Paul Scigalla, MD, PhD, is employed by Sugen Inc., San Francisco, California. |
Vol 136 - N° 1
P. 194-196 - juillet 2003 Retour au numéro
Article précédent
- Acute retinal necrosis following epidural steroid injections
- David J Browning
- Long-term results following pars plana vitrectomy with platelet concentrate in pediatric patients with traumatic macular hole
- Joachim Wachtlin, Claudia Jandeck, Simone Potthöfer, Ulrich Kellner, Michael H. Foerster
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?